Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03603925 · ClinicalTrials.gov registry record

Enhancing SUV Accuracy of PET/MR for Clinical Trial Qualification

A clinical trial, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
37
Enrollment target

NCT03603925 is a clinical trial that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 37 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03603925 has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
37 participants
Enrollment target

Study Summary

Standardized Uptake Values (SUVs), normalized activity concentration, measured using PET/MR have inaccuracies ≥ 20% which exceeds National Cancer Institute / American College of Radiology Imaging Network (NCI/ACRIN), Radiological Society of North America / Quantitative Imaging Biomarkers Alliance (RSNA/QIBA) specifications and disqualifies PET/MR from multicenter or cooperative group clinical trials. High inaccuracy is primarily due to poor attenuation correction (AC) owing to lack of computed tomography (CT) data. This study will develop acquisition and analyses methods to synthesize CT images from MR data that can be used to achieve SUVs that are within 5% of those obtained using PET/CT (reference standard), thus meeting accuracy requirements needed to qualify for multicenter trials. The overall goal of this research project is to validate clinically practical methods for producing MR-based attenuation correction information which is needed to produce quantitatively accurate PET images from a PET/MR scanner. Existing commercial PET/MR systems use methods that are inaccurate.

Interventions

  • DIAGNOSTIC_TEST Positron Emission Test / Magnetic Resonance (PET/MR)
  • DIAGNOSTIC_TEST Positron Emission Test / Computed Tomography (PET/CT)

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2019-06-17
Est. Completion 2021-04-07

Sponsor

Case Comprehensive Cancer Center

407 total trials

What the Registry Record Tells You About NCT03603925

The ClinicalTrials.gov registry entry for NCT03603925 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Positron Emission Test / Magnetic Resonance (PET/MR) is the first listed.

NCT03603925 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03603925 about?

NCT03603925 is a clinical study titled "Enhancing SUV Accuracy of PET/MR for Clinical Trial Qualification". Standardized Uptake Values (SUVs), normalized activity concentration, measured using PET/MR have inaccuracies ≥ 20% which exceeds National Cancer Institute / American College of Radiology Imaging Network (NCI/ACRIN), Radiological Society of North America / Quantitative Imaging Biomarkers Alliance (R...

What is the current status of trial NCT03603925?

This trial is currently completed. The enrollment target is 37 participants. The study started on 2019-06-17. Estimated completion is 2021-04-07.

What interventions are being tested in trial NCT03603925?

The interventions under investigation include: Positron Emission Test / Magnetic Resonance (PET/MR) (DIAGNOSTIC_TEST), Positron Emission Test / Computed Tomography (PET/CT) (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03603925?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.